ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : ¼ºñ½ºº°, Ä¡·á ºÐ¾ßº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Pharmaceutical Contract Sales Organizations Market Size, Share & Trends Analysis Report By Services (Personal, Non-personal Promotion), By Therapeutic Area, By End Use (Pharma, Biopharma Companies), By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1679387
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 02¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 150 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå ¼ºÀå°ú µ¿Çâ
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 181¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ̸ç, 2025-2030³â 8.83%ÀÇ CAGR·Î È®´ëµÉ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.
ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü(CSO)ÀÇ ³ôÀº ÆÇ¸Å ¼öŹÀ» À§ÇÑ ½Å±â¼ú äÅ÷ü, ¹ÙÀÌ¿ÀÀǾàǰ ¹× ÀúºÐÀÚ ÀǾàǰ ÆÇ¸Å È®´ë¿¡ ´ëÇÑ ÃÖÁ¾»ç¿ëÀÚÀÇ °ü½É Áõ°¡, ÀÚü ÆÇ¸Å °ü·Ã ºñ¿ë Àý°¨¿¡ ´ëÇÑ ¼ö¿ä ±ÞÁõÀº »ê¾÷ ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù. ÃÖ±Ù ¸î ³â µ¿¾È ½Å¾à Ãâ½Ã ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î, IQVIAÀÇ ¿¬±¸°³¹ß µ¿Çâ º¸°í¼¿¡ µû¸£¸é 2021³â¿¡´Â Àü ¼¼°èÀûÀ¸·Î 84°³ÀÇ »õ·Î¿î À¯È¿¹°ÁúÀÌ Ãâ½ÃµÇ¾úÀ¸¸ç, ÀÌ´Â Áö³ 5³â µ¿¾È 2¹è·Î Áõ°¡ÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ¼¼°è ½Å¾à Ãâ½ÃÀÇ Áõ°¡´Â ÆÇ¸Å ¼öŹ ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ Çâ»ó½Ãų °ÍÀ¸·Î ¿¹»óµÇ¸ç »ê¾÷ÀÇ ¼ºÀåÀ» Áö¿øÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. 󹿾àÀÇ ¸ÅÃâÀº ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Evaluate Pharma¿¡ µû¸£¸é 2021³â ¼¼°è ó¹æ¾à ¸ÅÃâÀº 1Á¶ 660¾ï ´Þ·¯, 2028³â¿¡´Â 1Á¶ 6,120¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦¾à ±â¾÷ÀÇ ÆÇ¸Å ¼ö¿ä Áõ°¡´Â ÆÒµ¥¹Í ÀÌÈÄ ÀǾàǰ CSO ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- ¼ºñ½ºº°·Î´Â 2024³â °³ÀÎ ÇÁ·Î¸ð¼Ç ºÎ¹®ÀÌ »ê¾÷À» ÁÖµµÇß½À´Ï´Ù. Á¦¾à±â¾÷ÀÇ ¿¬±¸°³¹ß Ȱµ¿ÀÌ È°¹ßÇØÁü¿¡ µû¶ó ½Å¾à Ãâ½Ã°¡ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ½Å¾à ½ÂÀÎÀº ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
- 2024³â Á¦¾à»çÀÇ ÃÖÁ¾ ¿ëµµ ºÎ¹®ÀÌ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇߴµ¥, ÀÌ´Â Á¦¾à»ç °£ Á¦Ç° ÆÇ¸Å °æÀïÀÌ Ä¡¿ÇØÁö¸é¼ ¿µ¾÷ Ȱµ¿À» Áö¿øÇÏ´Â È¿À²ÀûÀÎ ÆÀ¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁ³±â ¶§¹®À¸·Î ºÐ¼®µË´Ï´Ù.
- ºÏ¹Ì´Â 2024³â °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ Áö¿ª, ƯÈ÷ ¹Ì±¹¿¡¼´Â Áö³ ¸î ³â µ¿¾È »ó´çÇÑ ¼öÀÇ ÀǾàǰÀÌ Ãâ½ÃµÇ¾úÀ¸¸ç, ÀÌ´Â ÀÌ Áö¿ªÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.
- ¶ÇÇÑ, ÀÌ Áö¿ªÀÇ °ø°ø ±â°üÀº ÀÚ±Ý Áö¿øÀ» ÅëÇÑ ¿¬±¸°³¹ß Ȱµ¿ Áö¿ø¿¡ ²ÙÁØÈ÷ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÌ Áö¿ªÀÇ ¼ºÀåÀ» ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óºÎ ½ÃÀå Àü¸Á
- °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
- ½ÃÀå µ¿Çâ°ú Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- »ê¾÷ ºÐ¼® Åø
- Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- COVID-19ÀÇ ¿µÇ⠺м®
Á¦4Àå ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå : ¼ºñ½ºº°, ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå, ¼ºñ½º º¯µ¿ ºÐ¼®
- ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, ¼ºñ½ºº°, 2018-2030³â
- °³ÀÎ ÇÁ·Î¸ð¼Ç
- ÇÁ·Î¸ð¼Ç ¿µ¾÷ ÆÀ
- ÁÖ¿ä ¾îÄ«¿îÆ® °ü¸®
- °ø½Ç °ü¸®
- ºñ°³ÀÎ ÇÁ·Î¸ð¼Ç
- Medical Affairs Solutions
- Remote Medical Science Liaisons
- Nurse Educators
- ±âŸ
Á¦5Àå ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå : Ä¡·á ºÐ¾ßº°, ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå, Ä¡·á ºÐ¾ß º¯µ¿ ºÐ¼®
- ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå ±Ô¸ð¿Í µ¿Ç⠺м®, Ä¡·á ºÐ¾ßº°, 2018-2030³â
- Á¾¾çÇÐ
- ½ÉÇ÷°ü
- ½Å°æÇÐ
- °¨¿°Áõ
- ´ë»çÀå¾Ö
- Á¤Çü¿Ü°ú Áúȯ
- ±âŸ
Á¦6Àå ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå : ÃÖÁ¾ ¿ëµµº°, ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå, ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
- ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ±Ô¸ð¿Í µ¿Ç⠺м®, ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
- Á¦¾àȸ»ç
- ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷
Á¦7Àå Áö¿ª ºñÁî´Ï½º ºÐ¼®
- Áö¿ª ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®, 2018-2030³â
- ºÏ¹Ì
- ºÏ¹ÌÀÇ ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå, 2018-2030³â
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´
- À¯·´ÀÇ ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå, 2018-2030³â
- µ¶ÀÏ
- ¿µ±¹
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- µ§¸¶Å©
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå, 2018-2030³â
- ÀϺ»
- Áß±¹
- Àεµ
- Çѱ¹
- È£ÁÖ
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå, 2018-2030³â
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀǾàǰ ÆÇ¸Å ¼öʱâ°ü ½ÃÀå, 2018-2030³â
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- Äí¿þÀÌÆ®
Á¦8Àå °æÀï ±¸µµ
- ±â¾÷ ºÐ·ù
- ±â¾÷ ½ÃÀå »óȲ ºÐ¼®, 2024³â
- ±â¾÷ °³¿ä
- CMIC Holdings Co., Ltd.
- Axxelus
- EPS Corp.
- QFR Solutions
- MaBico
- Mednext Pharma Pvt. Ltd.
- Peak Pharma Solutions Inc.
- IQVIA, Inc.
- Promoveo Health
- Syneous Health
ksm
¿µ¹® ¸ñÂ÷
Pharmaceutical Contract Sales Organizations Market Growth & Trends:
The global pharmaceutical contract sales organizations market size is estimated to reach USD 18.14 billion by 2030, expanding at a CAGR of 8.83% from 2025 to 2030, according to a new report by Grand View Research, Inc. High adoption of new technologies for contract sales by pharmaceutical contract sales organizations (CSO), an increase in the interest among end-users to increase the sales of biopharmaceutical and small molecule drugs, and the surge in demand for reducing the cost associated with in-house sales are some of the key factors supporting the growth of the industry. Over the years, the number of new drug launches has increased.
For instance, according to the IQVIA report on R&D trends, 84 new active substances were launched globally in 2021, which was double as compared to the last five years. The increase in drug launches globally is expected to improve the demand for contract sales services, which is likely to support industry growth. Prescription drug sales are witnessing a steady rise. For instance, according to Evaluate Pharma, worldwide total prescription drug sales accounted for USD 1,066 billion in 2021 and will reach USD 1,612 billion by 2028. The growing demand for sales among pharmaceutical companies is expected to improve the demand for CSO services for pharmaceuticals in the post-pandemic period.
Pharmaceutical Contract Sales Organizations Market Report Highlights:
- Based on service, the personal promotion segment dominated the industry in 2024. A rise in the R&D activities of pharmaceutical companies is expected to increase the number of new drug launches, and approvals are expected to support the segment growth
- The pharmaceutical companies end-use segment held the largest revenue share in 2024 due to the high competition among pharmaceutical companies in product sales, promoting the demand for an efficient team to support their sales activities
- North America held the largest revenue share in 2024. A significant number of drugs were launched in the region in the previous years, especially in the U.S., which is one of the key factors supporting the region's growth
- Moreover, the region's public organization is steadily focused on supporting R&D activities by providing funding. This has further supported the region's growth
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.3. Information Analysis
- 1.3.1. Market Formulation & Data Visualization
- 1.4. Data Validation & Publishing
- 1.5. Information Procurement
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.2. Market Restraint Analysis
- 3.4. Industry Analysis Tools
- 3.4.1. Porter's Five Forces Analysis
- 3.4.2. PESTEL Analysis
- 3.4.3. COVID-19 Impact Analysis
Chapter 4. Pharmaceutical Contract Sales Organizations Market: Service Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Pharmaceutical Contract Sales Organizations Market; Service Movement Analysis
- 4.3. Pharmaceutical Contract Sales Organizations Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
- 4.4. Personal Promotion
- 4.4.1. Personal promotion market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2. Promotional sales team
- 4.4.2.1. Promotional sales team market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.3. Key account management
- 4.4.3.1. Key account management market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.4. Vacancy management
- 4.4.4.1. Vacancy management market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Non-personal promotion
- 4.5.1. Non-personal promotion market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5.2. Medical affairs solutions
- 4.5.2.1. Medical affairs solutions market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5.3. Remote medical science liaisons
- 4.5.3.1. Remote medical science liaisons market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5.4. Nurse educators
- 4.5.4.1. Nurse educators market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5.5. Others
- 4.5.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Pharmaceutical Contract Sales Organizations Market: Therapeutic Areas Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Pharmaceutical Contract Sales Organizations Market; Therapeutic Areas Movement Analysis
- 5.3. Pharmaceutical Contract Sales Organizations Market Size & Trend Analysis, by Therapeutic Areas, 2018 to 2030 (USD Million)
- 5.4. Oncology
- 5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Cardiovascular
- 5.5.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Neurology
- 5.6.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Infectious Diseases
- 5.7.1. Infectious Diseases market estimates and forecasts 2018 to 2030 (USD Million)
- 5.8. Metabolic Disorders
- 5.8.1. Metabolic Disorders market estimates and forecasts 2018 to 2030 (USD Million)
- 5.9. Orthopedic Diseases
- 5.9.1. Orthopedic Diseases market estimates and forecasts 2018 to 2030 (USD Million)
- 5.10. Others
- 5.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Pharmaceutical Contract Sales Organizations Market: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Pharmaceutical Contract Sales Organizations Market; End Use Movement Analysis
- 6.3. Pharmaceutical Contract Sales Organizations Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
- 6.4. Pharmaceutical Companies
- 6.4.1. Pharmaceutical market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Biopharmaceutical Companies
- 6.5.1. Biopharmaceutical Companies market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Regional Business Analysis
- 7.1. Regional Dashboard
- 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
- 7.3. North America
- 7.3.1. North America pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Competitive Scenario
- 7.3.2.3. Regulatory Framework
- 7.3.2.4. U.S. pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.3.3. Canada
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Competitive Scenario
- 7.3.3.3. Regulatory Framework
- 7.3.3.4. Canada pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.3.4. Mexico
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Competitive Scenario
- 7.3.4.3. Regulatory Framework
- 7.3.4.4. Mexico pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.4. Europe
- 7.4.1. Europe pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.4.2. Germany
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Germany pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.4.3. UK
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. UK pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.4.4. France
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. France pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.4.5. Italy
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Competitive Scenario
- 7.4.5.3. Regulatory Framework
- 7.4.5.4. Italy pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.4.6. Spain
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Competitive Scenario
- 7.4.6.3. Regulatory Framework
- 7.4.6.4. Spain pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.4.7. Denmark
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Competitive Scenario
- 7.4.7.3. Regulatory Framework
- 7.4.7.4. Denmark pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.4.8. Sweden
- 7.4.8.1. Key Country Dynamics
- 7.4.8.2. Competitive Scenario
- 7.4.8.3. Regulatory Framework
- 7.4.8.4. Sweden pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.4.9. Norway
- 7.4.9.1. Key Country Dynamics
- 7.4.9.2. Competitive Scenario
- 7.4.9.3. Regulatory Framework
- 7.4.9.4. Norway pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.5. Asia Pacific
- 7.5.1. Asia Pacific pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.5.2. Japan
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Japan pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.5.3. China
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. China pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.5.4. India
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. India pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.5.5. South Korea
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. South Korea pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.5.6. Australia
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Australia pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.5.7. Thailand
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Thailand pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.6. Latin America
- 7.6.1. Latin America pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.6.2. Brazil
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Brazil pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Argentina pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.7. MEA
- 7.7.1. MEA pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.7.2. South Africa
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. South Africa pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.7.3. Saudi Arabia
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Saudi Arabia pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.7.4. UAE
- 7.7.4.1. Key Country Dynamics
- 7.7.4.2. Competitive Scenario
- 7.7.4.3. Regulatory Framework
- 7.7.4.4. UAE pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
- 7.7.5. Kuwait
- 7.7.5.1. Key Country Dynamics
- 7.7.5.2. Competitive Scenario
- 7.7.5.3. Regulatory Framework
- 7.7.5.4. Kuwait pharmaceutical contract sales organizations market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Company Market Position Analysis, 2024
- 8.3. Company Profiles
- 8.3.1. CMIC Holdings Co., Ltd.
- 8.3.1.1. Company overview
- 8.3.1.2. Financial performance
- 8.3.1.3. Service benchmarking
- 8.3.1.4. Strategic initiatives
- 8.3.2. Axxelus
- 8.3.2.1. Company overview
- 8.3.2.2. Financial performance
- 8.3.2.3. Service benchmarking
- 8.3.2.4. Strategic initiatives
- 8.3.3. EPS Corp.
- 8.3.3.1. Company overview
- 8.3.3.2. Financial performance
- 8.3.3.3. Service benchmarking
- 8.3.3.4. Strategic initiatives
- 8.3.4. QFR Solutions
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Service benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. MaBico
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Service benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Mednext Pharma Pvt. Ltd.
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Service benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Peak Pharma Solutions Inc.
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Service benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. IQVIA, Inc.
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Service benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Promoveo Health
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Service benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. Syneous Health
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Service benchmarking
- 8.3.10.4. Strategic initiatives
°ü·ÃÀÚ·á